No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 38.9x · 10Y median 40.1x · 46th percentile · as of Oct 2, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-02T18:40:53.844Z. Latest historical point 2026-10-01. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Recursion Pharmaceuticals, Inc. (RXRX) stock was $4.07 as of Oct 2, 2026, 2:40 PM EDT, down 0.12% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -20.2% · 3-year avg -18.9%/yr · 5-year avg -28.6%/yr
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase.
Biotechnology · Salt Lake City, UT
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 4, 2026
33 days away
EPS Estimate
-0.24
Revenue Est.
$12.98M
Last Quarter Results
EPS
$-0.25
vs Estimate
$-0.23
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1RXRX | $2.13B | $4.07 | -0.12% | -20.21% | -28.56% | N/A | N/A |
| 2BEAM | $2.50B | $24.26 | -0.54% | +1.08% | -22.35% | N/A | vs RXRX |
| 3XRAY | $1.73B | $8.63 | -1.32% | -31.59% | -30.33% | -16.27% | vs RXRX |
| 4NTLA | $1.70B | $12.20 | +0.66% | -35.41% | -38.17% | -3.34% | vs RXRX |
| 5TMDX | $2.73B | $79.00 | +0.46% | -31.57% | +19.20% | N/A | vs RXRX |
| 6TDOC | $1.00B | $5.53 | -2.56% | -27.32% | -46.28% | -11.06% | vs RXRX |
forward FY estimate
N/A
$7.30M
vs Estimate
$10.97M
Consensus Rating
Based on 6 analysts
Average Price Target
$7.22
+77.5% upside
Low
$4.00
Current
$4.07
High
$10.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.23 | $-0.22 | $-0.21 | 4 |
| Quarter ending Dec 2026 | $-0.23 | $-0.22 | $-0.20 | 4 |
| Quarter ending Mar 2027 | $-0.61 | $-0.23 | $-0.06 | 1 |
| Quarter ending Jun 2027 | $-0.64 | $-0.23 | $-0.06 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.95 | $-0.90 | $-0.88 | 5 |
| FY 2027 | $-0.92 | $-0.90 | $-0.86 | 5 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $11.19M | $12.98M | $13.72M | 5 |
| Quarter ending Dec 2026 | $5.89M | $13.44M | $31.78M | 5 |
| Quarter ending Mar 2027 | $4.92M | $11.40M | $26.33M | 4 |
| Quarter ending Jun 2027 | $6.47M | $15.00M | $34.64M | 4 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $29.27M | $41.19M | $68.45M | 6 |
| FY 2027 | $30.08M | $54.80M | $88.16M | 6 |
